Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 6 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 9 patents granted in the last 365 days
Jazz Pharmaceuticals Research UK Limited maintains a patent portfolio in the Biotechnology & Pharmaceuticals technology area. There are 8 pending office actions currently active for this entity. This number reflects a steady stream of communication with patent authorities across their pending applications in the pharmaceutical sector.
The prosecution effort is distributed among 8 distinct examiners and spans 6 distinct art units. This high number of art units relative to the 8 pending office actions suggests a broad technical diversity within the company's biotechnology filings. With 8 distinct examiners involved, the company is navigating a wide variety of individual examination styles and interpretations of patent law across multiple specialized divisions.
MCKOY, QUINCY ANDRE is the busiest examiner for the portfolio, holding 1 busiest examiner pending office action. Given that each of the 8 pending office actions is assigned to a different person among the 8 distinct examiners, the workload is evenly distributed. This means the company's success is not tied to a single busiest examiner but is instead dependent on the outcomes of 8 separate and independent reviews across 6 different art units.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (14%) |
| Double-patenting + other | 1 (14%) |
| Multi-statute (no §101) | 5 (71%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCKOY, QUINCY ANDRE | 1 | 68.8% | +39.4% |
| CHANG, KYUNG SOOK | 1 | 60.4% | +40.9% |
| FOWLER, ALAN JEROME | 1 | 100.0% | +0.0% |
| BAUER, BRIANNA LEE | 1 | 100.0% | +0.0% |
| KAPUSHOC, STEPHEN THOMAS | 1 | 46.5% | +53.5% |
| ABDALHAMEED, MANAHIL MIRGHANI ALI | 1 | 50.3% | +38.2% |
| MATTISON, LORI K | 1 | 14.7% | +26.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18597717 | ORAL SOLID DOSAGE FORMS COMPRISING CANNABINOIDS | CHANG, KYUNG SOOK | 43d overdue |
| 17786949 | ORAL CANNABINOID FORMULATIONS | ABDALHAMEED, MANAHIL MIRGHANI ALI | 22d overdue |
| 18546254 | USE OF CANNABIDIVARIN IN THE TREATMENT OF SEIZURES ASSOCIATED WITH CANINE EPILEPSY | BAUER, BRIANNA LEE | 20d |
| 18258485 | IDENTIFICATION AND TREATMENT OF PATIENTS WITH EPILEPSY | KAPUSHOC, STEPHEN THOMAS | 34d |
| 18912442 | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | MCKOY, QUINCY ANDRE | — |
| 18560337 | DERIVATIVES OF CANNABIDIOL-C4 FOR THE TREATMENT OF EPILEPSY | FOWLER, ALAN JEROME | — |
| 15640033 | CANNABINOID FORMULATIONS | MATTISON, LORI K | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18597717 | ORAL SOLID DOSAGE FORMS COMPRISING CANNABINOIDS | CHANG, KYUNG SOOK | 43d overdue |
| 17786949 | ORAL CANNABINOID FORMULATIONS | ABDALHAMEED, MANAHIL MIRGHANI ALI | 22d overdue |
| 18258485 | IDENTIFICATION AND TREATMENT OF PATIENTS WITH EPILEPSY | KAPUSHOC, STEPHEN THOMAS | 34d |
| 18912442 | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | MCKOY, QUINCY ANDRE | — |
| 15640033 | CANNABINOID FORMULATIONS | MATTISON, LORI K | — |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| 1691 | 1 |
| 1623 | 1 |
| 1683 | 1 |
| 1622 | 1 |
| 1619 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18912442 | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | MCKOY, QUINCY ANDRE | — | §103§112 | Non-Final OA | — | Pending | Oct 10, 2024 |
| 18597717 | ORAL SOLID DOSAGE FORMS COMPRISING CANNABINOIDS | CHANG, KYUNG SOOK | 1613 | §103§112Other | Final Rejection | 43d overdue | Pending | Mar 06, 2024 |
| 18560337 | DERIVATIVES OF CANNABIDIOL-C4 FOR THE TREATMENT OF EPILEPSY | FOWLER, ALAN JEROME | 1691 | §102§103 | Non-Final OA | — | Pending | Nov 10, 2023 |
| 18546254 | USE OF CANNABIDIVARIN IN THE TREATMENT OF SEIZURES ASSOCIATED WITH CANINE EPILEPSY | BAUER, BRIANNA LEE | 1623 | §102§103§112Other | Non-Final OA | 20d | Pending | Aug 11, 2023 |
| 18258485 | IDENTIFICATION AND TREATMENT OF PATIENTS WITH EPILEPSY | KAPUSHOC, STEPHEN THOMAS | 1683 | §102§112 | Non-Final OA | 34d | Pending | Jun 20, 2023 |
| 17786949 | ORAL CANNABINOID FORMULATIONS | ABDALHAMEED, MANAHIL MIRGHANI ALI | 1622 | §101§103Other | Final Rejection | 22d overdue | Pending | Jun 17, 2022 |
| 15640033 | CANNABINOID FORMULATIONS | MATTISON, LORI K | 1619 | §103§112DP | Non-Final OA | — | Pending | Jun 30, 2017 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial